Placebo to match deucravacitinib tablet
Sponsors
Bristol Myers Squibb International Corporation, Bristol-Myers Squibb Services Unlimited Company
Conditions
Active Psoriatic ArthritisSystemic Lupus Erythematosus
Phase 2
Phase 3
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or had Previously Received TNFα Inhibitor Treatment
Active, not recruitingCTIS2023-506257-37-00
Start: 2021-10-29Target: 360Updated: 2025-10-20
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis who are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
Active, not recruitingCTIS2023-506256-25-00
Start: 2021-10-20Target: 326Updated: 2025-09-29